lixivaptan Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin 2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in Phase III clinical development for the treatment of Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.   Wikipedia

Chemistry

  • SMILES: Cc1ccc(F)cc1C(=O)Nc2ccc(C(=O)N3Cc4cccn4Cc5ccccc35)c(Cl)c2
  • InChIKey: PPHTXRNHTVLQED-UHFFFAOYSA-N
  • Mol. Mass: 473.94
  • ALogP: 6.05
  • ChEMBL Molecule:
    lixivaptan  
More Chemistry

Pharmacology

Alternative names

5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide | crtx-080 | lixivaptan | n-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide | vpa 985 | vpa-985 | way vpa-985 | way-vpa-985

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Body Fluids (Phase 3)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 2)

Hyponatremia (Phase 3)

Polycystic Kidney, Autosomal Dominant (Phase 3)

Polycystic Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue